EPIZYME INC's ticker is EPZM and the CUSIP is 29428V104. A total of 151 filers reported holding EPIZYME INC in Q3 2020. The put-call ratio across all filers is 2.70 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $109,000 | +581.2% | 74,339 | +422.1% | 0.00% | – |
| Q1 2022 | $16,000 | -63.6% | 14,239 | -18.8% | 0.00% | – |
| Q4 2021 | $44,000 | +388.9% | 17,539 | +1624.6% | 0.00% | – |
| Q1 2021 | $9,000 | -93.3% | 1,017 | -91.8% | 0.00% | – |
| Q4 2020 | $135,000 | -23.3% | 12,417 | -15.8% | 0.00% | -100.0% |
| Q3 2020 | $176,000 | +6.7% | 14,755 | +43.7% | 0.00% | 0.0% |
| Q2 2020 | $165,000 | +161.9% | 10,266 | +105.6% | 0.00% | 0.0% |
| Q2 2019 | $63,000 | – | 4,993 | +83116.7% | 0.00% | – |
| Q4 2018 | $0 | -100.0% | 6 | -99.5% | 0.00% | – |
| Q3 2018 | $12,000 | +1100.0% | 1,105 | +1525.0% | 0.00% | – |
| Q2 2017 | $1,000 | -96.6% | 68 | -97.7% | 0.00% | – |
| Q3 2016 | $29,000 | -12.1% | 2,966 | +9.9% | 0.00% | – |
| Q1 2016 | $33,000 | -36.5% | 2,700 | -16.6% | 0.00% | -100.0% |
| Q4 2015 | $52,000 | +550.0% | 3,238 | +440.6% | 0.00% | – |
| Q3 2015 | $8,000 | +166.7% | 599 | +343.7% | 0.00% | – |
| Q2 2015 | $3,000 | +200.0% | 135 | +285.7% | 0.00% | – |
| Q1 2015 | $1,000 | 0.0% | 35 | -5.4% | 0.00% | – |
| Q3 2014 | $1,000 | -99.7% | 37 | -99.7% | 0.00% | -100.0% |
| Q1 2014 | $304,000 | – | 13,364 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 31,833,334 | $47,750,000 | 19.42% |
| MPM BioImpact LLC | 3,425,202 | $3,939,000 | 1.06% |
| Palo Alto Investors LP | 6,774,541 | $7,791,000 | 0.60% |
| Foresite Capital Management I, LLC | 143,759 | $165,000 | 0.29% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 6,603,870 | $7,594,000 | 0.23% |
| Rock Springs Capital Management LP | 7,267,696 | $8,358,000 | 0.21% |
| BP PLC | 24,687 | $28,000 | 0.16% |
| NewGen Asset Management Ltd | 250,000 | $288,000 | 0.13% |
| GSA CAPITAL PARTNERS LLP | 467,836 | $538,000 | 0.07% |
| Frazier Life Sciences Management, L.P. | 739,369 | $850,000 | 0.07% |